Collegium Pharmaceutical (Collegium Pharmaceutical) Days Sales Outstanding : 111.52 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical Days Sales Outstanding?

Collegium Pharmaceutical's average Accounts Receivable for the three months ended in Mar. 2024 was $177.1 Mil. Collegium Pharmaceutical's Revenue for the three months ended in Mar. 2024 was $144.9 Mil. Hence, Collegium Pharmaceutical's Days Sales Outstanding for the three months ended in Mar. 2024 was 111.52.

The historical rank and industry rank for Collegium Pharmaceutical's Days Sales Outstanding or its related term are showing as below:

COLL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.22 Med: 103.25 Max: 454.17
Current: 113.66

During the past 11 years, Collegium Pharmaceutical's highest Days Sales Outstanding was 454.17. The lowest was 57.22. And the median was 103.25.

COLL's Days Sales Outstanding is ranked worse than
80.46% of 998 companies
in the Drug Manufacturers industry
Industry Median: 71.845 vs COLL: 113.66

Collegium Pharmaceutical's Days Sales Outstanding declined from Mar. 2023 (114.17) to Mar. 2024 (111.52).

Collegium Pharmaceutical Days Sales Outstanding Historical Data

The historical data trend for Collegium Pharmaceutical's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Days Sales Outstanding Chart

Collegium Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

92.82

91.99

124.69

113.67

116.77

Collegium Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															114.17	116.67	116.58	110.11	111.52

Competitive Comparison of Collegium Pharmaceutical's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Collegium Pharmaceutical's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Days Sales Outstanding falls into.

Collegium Pharmaceutical Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Collegium Pharmaceutical's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (183.119	+	179.525)	/	2 )	/	566.767	*	365
=	181.322					/	566.767	*	365
=	116.77

Collegium Pharmaceutical's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (179.525	+	174.693)	/	2 )	/	144.923	*	365 / 4
=	177.109					/	144.923	*	365 / 4
=	111.52

Collegium Pharmaceutical (NAS:COLL) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Collegium Pharmaceutical Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Collegium Pharmaceutical (Collegium Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

354:Germany

Address

100 Technology Center Drive, Stoughton, MA, USA, 02072

Website

https://www.collegiumpharma.com

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

Executives

Scott Dreyer	officer: EVP & Chief Commercial Officer	780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Joseph Ciaffoni	director, officer: President and CEO	100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Shirley R. Kuhlmann	officer: EVP and General Counsel	780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Tupper Colleen	officer: EVP & Chief Financial Officer	C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Rita J. Balice-gordon	director	C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
John Gordon Freund	director	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane	director	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Thomas B Smith	officer: EVP and Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Richard Malamut	officer: EVP and Chief Medical Officer	100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming	officer: Vice President, Product Devlp	780 DEDHAM STREET, SUITE 800, CANTON MA 02021